BidaskClub upgraded shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) from a sell rating to a hold rating in a research report sent to investors on Saturday.
Several other analysts also recently weighed in on the company. Cantor Fitzgerald set a $235.00 target price on GW Pharmaceuticals PLC- and gave the company a buy rating in a research note on Thursday, July 12th. ValuEngine downgraded GW Pharmaceuticals PLC- from a buy rating to a hold rating in a research note on Thursday, August 2nd. Bank of America boosted their price objective on GW Pharmaceuticals PLC- from $170.00 to $200.00 and gave the stock a buy rating in a research note on Tuesday, June 26th. Zacks Investment Research raised GW Pharmaceuticals PLC- from a hold rating to a buy rating and set a $148.00 price objective on the stock in a research note on Tuesday, April 24th. Finally, Cowen reissued a buy rating and issued a $165.00 price objective on shares of GW Pharmaceuticals PLC- in a research note on Wednesday, May 9th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of Buy and an average price target of $175.29.
GW Pharmaceuticals PLC- traded down $0.96, hitting $134.96, during mid-day trading on Friday, Marketbeat.com reports. 207,860 shares of the company’s stock traded hands, compared to its average volume of 339,874. The company has a quick ratio of 11.22, a current ratio of 8.67 and a debt-to-equity ratio of 0.01. GW Pharmaceuticals PLC- has a one year low of $96.42 and a one year high of $164.76.
Institutional investors and hedge funds have recently bought and sold shares of the company. Rothschild Investment Corp IL raised its stake in shares of GW Pharmaceuticals PLC- by 70.5% in the 2nd quarter. Rothschild Investment Corp IL now owns 20,332 shares of the biopharmaceutical company’s stock worth $2,837,000 after buying an additional 8,405 shares in the last quarter. Fox Run Management L.L.C. bought a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter worth $481,000. Wells Fargo & Company MN raised its stake in shares of GW Pharmaceuticals PLC- by 20.6% in the 1st quarter. Wells Fargo & Company MN now owns 29,172 shares of the biopharmaceutical company’s stock worth $3,288,000 after buying an additional 4,987 shares in the last quarter. RFG Advisory Group LLC bought a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter worth $410,000. Finally, LPL Financial LLC grew its holdings in shares of GW Pharmaceuticals PLC- by 9.0% in the 1st quarter. LPL Financial LLC now owns 8,418 shares of the biopharmaceutical company’s stock worth $948,000 after acquiring an additional 692 shares during the last quarter. 72.78% of the stock is currently owned by institutional investors.
GW Pharmaceuticals PLC- Company Profile
GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.
Further Reading: Outstanding Shares and The Effect on Share Price
Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.